Ashvattha Therapeutics, Inc.
Nanomedicine therapeutics that traverse tissue barriers to target activated cells in inflamed regions
- Sector
- Biotech
- Headquarters
- REDWOOD CITY, CA
- Founded
- 2015
- Latest Form D
- $7.7M, May 2021
- Total capital
- $8.9M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $8.9M
- 6 Form D · last May 2021
- 66 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 32 pending · first 2023
- Rank in peer group#339 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 6th filing$7.7M
- Private capital raisedForm D · SEC · 5th filing$250K
- Private capital raisedForm D · SEC · 4th filing$200K
- Private capital raisedForm D · SEC · 3rd filing$400K
- Private capital raisedForm D · SEC · 2nd filing$37K
- Private capital raisedForm D · SEC · 1st filing$300K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#339 · top 23%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Jeffrey ClelandResearcherExecutive OfficerLinked by 3 patents
- Barbara SlusherDirectorNamed in SEC Form D filings
- George MontgomeryDirectorNamed in SEC Form D filings
- Jay ZaveriDirectorNamed in SEC Form D filings
- Justin HanesExecutive OfficerNamed in SEC Form D filings
- Kannan RangaramanujamExecutive Officer, DirectorNamed in SEC Form D filings
Show all 8 people
- Sujatha KannanExecutive OfficerNamed in SEC Form D filings
- Yuhang ZhaoDirectorNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 35- PendingDendrimer Compositions And Methods For Drug Delivery To The EyeUSPTOApplication 18825168
- PendingDendrimer Compositions And Methods For Treatment Of Severe Acute Respiratory Distress SyndromeUSPTOApplication 18444218
- PendingDendrimer Conjugates And Methods Of Use ThereofUSPTOApplication 18568516
Show all 35 patent records
- Dendrimer Compositions And Methods For Drug Delivery To The EyeJul 31, 2025 · Application 18825168Pending
- Dendrimer Compositions And Methods For Treatment Of Severe Acute Respiratory Distress SyndromeJan 9, 2025 · Application 18444218Pending
- Dendrimer Conjugates And Methods Of Use ThereofJan 9, 2025 · Application 18568516Pending
- Dendrimer Compositions And Methods For Drug Delivery To The EyeOct 22, 2024 · US 12,121,585Granted
- Methods Of Treating Severe InflammationMar 19, 2024 · US 11,931,418Granted
- Dendrimer Compositions And Methods For Drug Delivery To Injured KidneyNov 16, 2023 · Application 18016262Pending
- Triantennary N-acetylgalactosamine Modified Hydroxyl Polyamidoamine Dendrimers And Methods Of Use ThereofJul 27, 2023 · Application 17782596Pending
- Dendrimer Compositions And Methods For Drug Delivery To The EyeMar 28, 2023 · US 11,612,660Granted
- Dendrimer Compositions And Methods For Drug DeliveryJun 10, 2021 · Application 17112541Pending
- Dendrimer Compositions And Methods For Drug Delivery To Injured KidneyApplication PCTUS2021042097Pending
- Dendrimer Conjugates And Methods Of Use ThereofApplication 63209348Pending
- Radiolabeled Ether Dendrimer Conjugates For Imaging And RadiotherapyApplication 63187851Pending
- Dendrimer Compositions And Methods For Treatment Of Severe Acute Respiratory Distress SyndromeApplication PCTUS2021029139Pending
- Dendrimer Compositions And Methods For Drug DeliveryApplication PCTUS2020063332Pending
- Triantennary N-acetylgalactosamine Modified Hydroxyl Polyamidoamine Dendrimers And Methods Of Use ThereofApplication PCTUS2020063342Pending
- Dendrimer Compositions And Methods For Drug Delivery To The EyeApplication PCTUS2020063347Pending
- Dendrimer Compositions And Methods For Drug DeliveryApplication 63108186Pending
- Radiolabeled Ether Dendrimer Conjugates For Pet Imaging And RadiotherapyApplication 63108230Pending
- Dendrimer Compositions And Methods For Drug Delivery To The EyeApplication 63108234Pending
- Triantennary N-acetylgalactosamine Modified Hydroxyl Polyamidoamine Dendrimers And Methods Of Use ThereofApplication 63086109Pending
- Triantennary N-acetylgalactosamine Modified Hydroxyl Polyamidoamine Dendrimers And Methods Of Use ThereofApplication 63067155Pending
- Dendrimer Compositions And Methods For Drug Delivery To Injured KidneyApplication 63053228Pending
- Dendrimer Compositions And Methods For Drug Delivery To The EyeApplication 63021023Pending
- Dendrimer Compositions And Methods For Treatment Of Severe Acute Respiratory Distress SyndromeApplication 63015131Pending
- Dendrimer Compositions And Methods For Drug Delivery To The EyeApplication 62943724Pending
- CSF1R Inhibitor Dendrimer Conjugates And Uses ThereofApplication PCTUS2025025976Pending
- Dendrimer Compositions And Methods For Drug DeliveryApplication 62943705Pending
- Dendrimer Formulations And Uses ThereofApplication PCTUS2025025993Pending
- Radiolabeled Dendrimer Conjugates And Methods Of Use ThereofApplication PCTUS2025023748Pending
- CSF1R Inhibitor Dendrimer Conjugates And Uses ThereofApplication 63637601Pending
- Dendrimer Snac Formulations And Uses ThereofApplication 63637545Pending
- Radiolabeled Dendrimer Conjugates And Methods Of Use ThereofApplication 63631163Pending
- Dendrimer Conjugates And Methods Of Use ThereofApplication PCTUS2022033112Pending
- Dendrimer Conjugates And Methods Of Use ThereofApplication 63327301Pending
- Radiolabeled Ether Dendrimer Conjugates For Pet Imaging And RadiotherapyApplication PCTUS2021057430Pending
Related companies, and why
- Noema PharmaSimilar federal contract value in Biotech · null in contracts
- Cerium Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- KallyopeSimilar federal contract value in Biotech · null in contracts
- PALATIN TECHNOLOGIES INCSimilar federal contract value in Biotech · null in contracts
- BioIncept, LLCSimilar federal contract value in Biotech · null in contracts
- Diceros Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .